|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||||||||||
  Journal of Cardiovascular ElectrophysiologyVolume 17 Issue 2, Pages 210 - 212 Published Online: 14 Sep 2005 Journal compilation © 2010 Wiley Periodicals, Inc.
Abstract | References | Full Text: HTML, PDF (Size: 208K) | Related Articles | Citation Tracking  Failure of Cilostazol in the Prevention of Ventricular Fibrillation in a Patient with Brugada Syndrome Manuscript received 7 April 2005; Revised manuscript received 1 June 2005; Accepted for publication 3 June 2005. Copyright 2005 by Futura Publishing Company, Inc. KEYWORDS
Brugada syndrome
•
ventricular fibrillation
•
cilostazol
Cilostazol Does Not Prevent VF in Brugada Syndrome. (J Cardiovasc Electrophysiol, Vol. 17, pp. 210-212, February 2006) ABSTRACTThe ECG appearance in Brugada syndrome is caused by failure of the dome of the action potential to develop. Increased activity of the I(to) current in epicardial cells generates a transmural gradient with repolarization dispersion between the epicardium and the endocardium in the right ventricular wall, thus favoring the development of VF by a phase 2 reentry mechanism. The efficacy of cilostazol for the management of these arrhythmias has been reported. This drug is a phosphodiesterase inhibitor with positive chronotropic properties, thus blocking outward potassium currents I(to) in the myocardial tissue. We present a patient with Brugada syndrome with an implantable cardioverter defibrillator (ICD), who suffered multiple ICD discharges due to VF during therapy with this drug. Received: 07 April 2005; First Revision: 01 June 2005; Accepted: 03 June 2005; | 
|
